---
title: Vaccine schedule recommendations and updates for patients with hematologic
  malignancy post-hematopoietic cell transplant or CAR T-cell therapy
date: '2023-07-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37515788/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230730180744&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Revaccination after receipt of a hematopoietic cell transplant (HCT)
  or cellular therapies is a pillar of patient supportive care, with the potential
  to reduce morbidity and mortality linked to vaccine-preventable infections. This
  review synthesizes national, international, and expert consensus vaccination schedules
  post-HCT and presents evidence regarding the efficacy of newer vaccine formulations
  for pneumococcus, recombinant zoster vaccine, and coronavirus disease 2019 in patients
  ...
disable_comments: true
---
Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to vaccine-preventable infections. This review synthesizes national, international, and expert consensus vaccination schedules post-HCT and presents evidence regarding the efficacy of newer vaccine formulations for pneumococcus, recombinant zoster vaccine, and coronavirus disease 2019 in patients ...